Allergic Asthma - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Allergic Asthma

The Experts below are selected from a list of 57645 Experts worldwide ranked by ideXlab platform

Allergic Asthma – Free Register to Access Experts & Abstracts

Jae Hyun Lee – One of the best experts on this subject based on the ideXlab platform.

  • soluble cd93 in Allergic Asthma
    Scientific Reports, 2020
    Co-Authors: Hye Jung Park, Heejae Han, Kyung Hee Park, Kyoung Yong Jeong, Jung Won Park, Jae Hyun Lee
    Abstract:

    CD93 has been shown critical roles in inflammatory and immune diseases. However, in Allergic Asthma, the potential roles of soluble CD93 (sCD93) have not been well studied. We conducted house dust mite (HDM) stimulation with Der p 1 in BEAS-2B and U937 cells, followed by treatment with dexamethasone or small interfering RNA against CD93. A HDM-induced murine Allergic Asthma model was also established. We estimated the power of sCD93 to predict Allergic Asthma in a retrospective post-hoc analysis containing 96 human samples. HDM-stimulated BEAS-2B cells showed increased mRNA expression levels of IL-6, IL-8, IL-33, TSLP, and CD93. The CD93 level in culture supernatants steadily increased for 24 h after allergen stimulation, which was significantly suppressed by both dexamethasone and CD93 silencing. CD93 silencing increased IL-6 and TSLP, but not IL-33 levels in culture supernatants. HDM-induced Asthma mice showed significant airway hyperresponsiveness and inflammation with Th2 cytokine activation, along with decreased CD93 expression in bronchial epithelial cells and lung homogenates but increased serum CD93 levels. The sCD93 level in Asthma patients was significantly higher than that in healthy controls and could predict Asthma diagnosis with moderate sensitivity (71.4%) and specificity (82.4%) (AUC = 0.787, P < 0.001). The level of sCD93 which has potential role to predict Asthma significantly increased after HDM stimulation via IL-6 and TSLP in vitro and in vivo.

  • Soluble CD93 in Allergic Asthma
    Scientific reports, 2020
    Co-Authors: Hye Jung Park, Heejae Han, Kyung Hee Park, Kyoung Yong Jeong, Jung Won Park, Jae Hyun Lee
    Abstract:

    CD93 has been shown critical roles in inflammatory and immune diseases. However, in Allergic Asthma, the potential roles of soluble CD93 (sCD93) have not been well studied. We conducted house dust mite (HDM) stimulation with Der p 1 in BEAS-2B and U937 cells, followed by treatment with dexamethasone or small interfering RNA against CD93. A HDM-induced murine Allergic Asthma model was also established. We estimated the power of sCD93 to predict Allergic Asthma in a retrospective post-hoc analysis containing 96 human samples. HDM-stimulated BEAS-2B cells showed increased mRNA expression levels of IL-6, IL-8, IL-33, TSLP, and CD93. The CD93 level in culture supernatants steadily increased for 24 h after allergen stimulation, which was significantly suppressed by both dexamethasone and CD93 silencing. CD93 silencing increased IL-6 and TSLP, but not IL-33 levels in culture supernatants. HDM-induced Asthma mice showed significant airway hyperresponsiveness and inflammation with Th2 cytokine activation, along with decreased CD93 expression in bronchial epithelial cells and lung homogenates but increased serum CD93 levels. The sCD93 level in Asthma patients was significantly higher than that in healthy controls and could predict Asthma diagnosis with moderate sensitivity (71.4%) and specificity (82.4%) (AUC = 0.787, P 

Dennis K. Ledford – One of the best experts on this subject based on the ideXlab platform.

  • Immunotherapy for Allergic Asthma
    Medical Clinics of North America, 2002
    Co-Authors: Nina C. Ramirez, Dennis K. Ledford
    Abstract:

    Specific allergen immunotherapy is an effective treatment of Allergic Asthma. Double-blind studies provide proof of benefit, although seasonal or intermittent Asthma consistently responds better than perennial Asthma. Advantages of immunotherapy compared with most pharmacotherapies include modification of the natural history of Allergic disease, reduction of need for chronic medication, and treatment of both upper and lower airway disease simultaneously. Improvements in immunotherapy occurred in the later portion of the twentieth century because of enhanced understanding of immunotherapy’s mechanism of action, recognition of the dose effect, and improved quality and consistency of allergen vaccines. Purified inhibitors of specific mediators of the Allergic response, products of biotechnology, will probably lead to improvements of immunotherapy of Asthma in the twenty-first century. The future of immunotherapy and other immunomodulation of Allergic Asthma is promising.

Michelle M Epstein – One of the best experts on this subject based on the ideXlab platform.

Hye Jung Park – One of the best experts on this subject based on the ideXlab platform.

  • soluble cd93 in Allergic Asthma
    Scientific Reports, 2020
    Co-Authors: Hye Jung Park, Heejae Han, Kyung Hee Park, Kyoung Yong Jeong, Jung Won Park, Jae Hyun Lee
    Abstract:

    CD93 has been shown critical roles in inflammatory and immune diseases. However, in Allergic Asthma, the potential roles of soluble CD93 (sCD93) have not been well studied. We conducted house dust mite (HDM) stimulation with Der p 1 in BEAS-2B and U937 cells, followed by treatment with dexamethasone or small interfering RNA against CD93. A HDM-induced murine Allergic Asthma model was also established. We estimated the power of sCD93 to predict Allergic Asthma in a retrospective post-hoc analysis containing 96 human samples. HDM-stimulated BEAS-2B cells showed increased mRNA expression levels of IL-6, IL-8, IL-33, TSLP, and CD93. The CD93 level in culture supernatants steadily increased for 24 h after allergen stimulation, which was significantly suppressed by both dexamethasone and CD93 silencing. CD93 silencing increased IL-6 and TSLP, but not IL-33 levels in culture supernatants. HDM-induced Asthma mice showed significant airway hyperresponsiveness and inflammation with Th2 cytokine activation, along with decreased CD93 expression in bronchial epithelial cells and lung homogenates but increased serum CD93 levels. The sCD93 level in Asthma patients was significantly higher than that in healthy controls and could predict Asthma diagnosis with moderate sensitivity (71.4%) and specificity (82.4%) (AUC = 0.787, P < 0.001). The level of sCD93 which has potential role to predict Asthma significantly increased after HDM stimulation via IL-6 and TSLP in vitro and in vivo.

  • Soluble CD93 in Allergic Asthma
    Scientific reports, 2020
    Co-Authors: Hye Jung Park, Heejae Han, Kyung Hee Park, Kyoung Yong Jeong, Jung Won Park, Jae Hyun Lee
    Abstract:

    CD93 has been shown critical roles in inflammatory and immune diseases. However, in Allergic Asthma, the potential roles of soluble CD93 (sCD93) have not been well studied. We conducted house dust mite (HDM) stimulation with Der p 1 in BEAS-2B and U937 cells, followed by treatment with dexamethasone or small interfering RNA against CD93. A HDM-induced murine Allergic Asthma model was also established. We estimated the power of sCD93 to predict Allergic Asthma in a retrospective post-hoc analysis containing 96 human samples. HDM-stimulated BEAS-2B cells showed increased mRNA expression levels of IL-6, IL-8, IL-33, TSLP, and CD93. The CD93 level in culture supernatants steadily increased for 24 h after allergen stimulation, which was significantly suppressed by both dexamethasone and CD93 silencing. CD93 silencing increased IL-6 and TSLP, but not IL-33 levels in culture supernatants. HDM-induced Asthma mice showed significant airway hyperresponsiveness and inflammation with Th2 cytokine activation, along with decreased CD93 expression in bronchial epithelial cells and lung homogenates but increased serum CD93 levels. The sCD93 level in Asthma patients was significantly higher than that in healthy controls and could predict Asthma diagnosis with moderate sensitivity (71.4%) and specificity (82.4%) (AUC = 0.787, P 

Nina C. Ramirez – One of the best experts on this subject based on the ideXlab platform.

  • Immunotherapy for Allergic Asthma
    Medical Clinics of North America, 2002
    Co-Authors: Nina C. Ramirez, Dennis K. Ledford
    Abstract:

    Specific allergen immunotherapy is an effective treatment of Allergic Asthma. Double-blind studies provide proof of benefit, although seasonal or intermittent Asthma consistently responds better than perennial Asthma. Advantages of immunotherapy compared with most pharmacotherapies include modification of the natural history of Allergic disease, reduction of need for chronic medication, and treatment of both upper and lower airway disease simultaneously. Improvements in immunotherapy occurred in the later portion of the twentieth century because of enhanced understanding of immunotherapy’s mechanism of action, recognition of the dose effect, and improved quality and consistency of allergen vaccines. Purified inhibitors of specific mediators of the Allergic response, products of biotechnology, will probably lead to improvements of immunotherapy of Asthma in the twenty-first century. The future of immunotherapy and other immunomodulation of Allergic Asthma is promising.